Tafenoquine
|
|
|
- CAS-Nr.
- 106635-80-7
- Englisch Name:
- Tafenoquine
- Synonyma:
- Krintafe;Tafenoquine;SB252263-AAB;SB 252263-AAB;TafenoIquine.;tafenoquine,Etaquine,WR 238605,SB-252263;WR-238605, WR 238605, WR238605, SB-252263-AAB;WR 238605; WR238605; WR-238605; SB-252263; SB 252263; SB252263;4-[5-[3-(Trifluoromethyl)phenoxy]-2,6-dimethoxy-4-methyl-8-quinolinylamino]-1-pentanamine;N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl}-1,4-pentanediamine
- CBNumber:
- CB51075086
- Summenformel:
- C24H28F3N3O3
- Molgewicht:
- 463.49
- MOL-Datei:
- 106635-80-7.mol
|
Tafenoquine Eigenschaften
- Schmelzpunkt:
- 60 - 63°C
- Siedepunkt:
- 565.6±50.0 °C(Predicted)
- Dichte
- 1.237±0.06 g/cm3(Predicted)
- storage temp.
- 4°C
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 10.36±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Dark Orange to Very Dark Orange
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Tafenoquine Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Tafenoquine is a pharmaceutical developed for the treatment of Plasmodium vivax malaria. Tafenoquine is also being explored for pharmaceutical use for inhibition of Toxoplasma gondii growth.
Pharmazeutische Anwendungen
Etaquine. A synthetic 8-aminoquinoline, formulated as the
succinate for oral administration. Tafenoquine is an effective
schizonticide against P. falciparum and P. vivax. It is also
active against the pre-erythrocytic stages of these species and
the hypnozoites of P. vivax. A dosage of 100 mg base corresponds
to 125 mg salt. Oral absorption is slow with a maximum
plasma concentration reached after 12 h. The half-life is
2 weeks, significantly longer than that of primaquine. It is not
eliminated via the kidneys. Toxicity and side effects are similar
to those of primaquine. Development of methemoglobinemia
is common. Patients with G6PD deficiency may develop
severe hemolysis.
It is in clinical development for the treatment and prophylaxis
of P. vivax malaria and for the treatment of P. falciparum
infection.
Tafenoquine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Tafenoquine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 39)Lieferanten
- Tafenoquine
- 4-[5-[3-(Trifluoromethyl)phenoxy]-2,6-dimethoxy-4-methyl-8-quinolinylamino]-1-pentanamine
- 8-[(4-Amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinoline
- N4-(2,6-diMethoxy-4-Methyl-5-(3-(trifluoroMethyl)phenoxy)quinolin-8-yl)pentane-1,4-diaMine
- N4-{2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl}-1,4-pentanediamine
- WR 238605; WR238605; WR-238605; SB-252263; SB 252263; SB252263
- WR-238605, WR 238605, WR238605, SB-252263-AAB; SB252263-AAB; SB 252263-AAB; TAFENOQUINE; KRINTAFE
- Krintafe
- SB 252263-AAB
- SB252263-AAB
- WR-238605, WR 238605, WR238605, SB-252263-AAB
- tafenoquine,Etaquine,WR 238605,SB-252263
- 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-
- TafenoIquine.
- 106635-80-7
